Demonstrates small-molecule strategies to inhibit YAP signaling in cancer models, suggesting new treatment avenues.
The Hippo–YAP pathway has emerged as a central regulator of tissue growth and oncogenesis, yet remains resistant to conventional pharmacological targeting. Patent application WO 2026/044133 A1 discloses small-molecule strategies that modulate YAP activity through transcriptional complex disruption and protein stability interference. Robust cellular validation across YAP-dependent cancer models establishes proof of concept for tractable YAP inhibition, with implications spanning oncology and regenerative medicine.
No takes yet. Share an insight, caveat, or question.
Renner et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: